Comparing GLP-1 Receptor Agonists with Empagliflozin or Dapagliflozin in People with Fatty Liver Disease and Heart Failure
Updated
Abstract
Treatment selection may confound comparisons of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in adults with metabolic dysfunction-associated steatotic liver disease and heart failure.
- Observational studies may be affected by biases related to treatment choices.
- Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors are both used in treating metabolic dysfunction-associated steatotic liver disease and heart failure.
- Confounding factors could impact the effectiveness and safety comparisons between these two classes of medications.
Simplified